癌症中的脂肪组织（AT）消耗是一种早期分解代谢事件，会对结果产生负面影响。循环 miRNA 可能会促进体重减轻和恶病质。我们测量了与 AT 改变相关的循环 miRNA，并比较了 i) 胃肠道 (GI) 癌症患者和对照，ii) 恶病质和非恶病质癌症患者，以及 iii) 根据肥胖水平及其分布之间的水平。考虑患有良性疾病的受试者作为对照。通过皮下 AT 面积 (SAT)、内脏 AT 面积和总 AT 面积 (TAT) 的 CT 扫描评估恶病质并评估肥胖情况。通过 RT-qPCR 测量血浆中涉及的 miRNA。纳入了 37 名初治胃肠道癌症患者和 14 名对照者。与非恶病质患者相比，恶病质患者的 SAT 较低 (p < 0.05)。在癌症患者中，我们发现与对照组相比，miR-26a、miR-128、miR-155 和 miR-181a 水平较高（p < 0.05）。与 BMI ≥ 25 的癌症患者相比，BMI < 25 kg/m2 的癌症患者的 miR-26a 水平更高 (p = 0.035)。与对照组相比，恶病质和非恶病质组中的 miR-26a 和 miR-181a 较高（p < 0.05）。 miR-155 证实了恶病质和对照之间的差异（p < 0.001），但非恶病质与对照之间没有差异（p = 0.072）。与无恶病质和高 TAT 的恶病质患者相比，低 TAT 恶病质患者的 MiR-155 较高（p = 0.036）。我们的数据证实了癌症和恶病质中参与 AT 代谢的特定和不同 miRNA 的调节。患有恶病质和低肥胖的患者中 MiR-155 水平较高，这对胃肠道癌症患者的致病机制和临床后果有影响。版权所有 © 2024 Tambaro、Imbimbo、Pace、Amabile、Rizzo、Orlando、Lauteri、Ramaccini、Catalano、Nigri 、穆斯卡里托利和莫尔菲诺。

Adipose tissue (AT) wasting in cancer is an early catabolic event with negative impact on outcomes. Circulating miRNAs may promote body weight loss and cachexia. We measured circulating miRNAs linked to AT alterations and compared their levels between i) gastrointestinal (GI) cancer patients and controls, ii) cachectic and non-cachectic cancer patients, and iii) according to adiposity level and its distribution.Patients with GI cancer and subjects with benign diseases as controls were considered. Cachexia was assessed and adiposity evaluated by CT-scan for subcutaneous AT area (SAT), visceral AT area and the total AT area (TAT). MiRNAs involved were measured in plasma by RT-qPCR.37 naïve GI cancer patients and 14 controls were enrolled. Patients with cachexia presented with lower SAT compared to non-cachectic (p < 0.05). In cancer patients, we found higher levels of miR-26a, miR-128, miR-155 and miR-181a vs. controls (p < 0.05). Cancer patients with BMI < 25 kg/m2 showed higher levels of miR-26a vs. those with BMI ≥ 25 (p = 0.035). MiR-26a and miR-181a were higher in cachectic and non-cachectic vs. controls (p < 0.05). Differences between cachectic and controls were confirmed for miR-155 (p < 0.001) but not between non-cachectic vs. control (p = 0.072). MiR-155 was higher in cachectic patients with low TAT vs. those without cachexia and high TAT (p = 0.036).Our data confirm a modulation of specific and different miRNAs involved in AT metabolism in cancer and cachexia. MiR-155 levels were higher in patients presenting with cachexia and low adiposity with implications in the pathogenic mechanisms and clinical consequences of GI cancer patients.Copyright © 2024 Tambaro, Imbimbo, Pace, Amabile, Rizzo, Orlando, Lauteri, Ramaccini, Catalano, Nigri, Muscaritoli and Molfino.